⌕
Vaxcyte · PCVX · Nasdaq
Tenet 46 · Mixed
Compare
$59.40−3.59%At closeTenet 46 · Mixed
$59.40−2.21 (−3.59%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Vaxcyte (PCVX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice
Business enginePre-revenue: no positive revenue in any year through FY25, so the growth and margin read is withheld. Worth your attention in FY25: Share count (+162.1%). Visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼65.2%
−766.6
FY21→FY25CAGR —
Free cash flow ($M)▼40.9%
−669.3
FY21→FY25CAGR —
Diluted EPS▼48.2%
−5.63
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+162.1%

51.9mn → 136.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.

Capex
$13.7M

−38.9% YoY in FY25.

What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)0.0Revenue0.0COGS0.0Gross profit−794.3R&D−129.4SG&A−923.7Op income157.0Tax & other−766.6Net income

Margin trend · direction beats level
108530%sector median net margin ~3%FY21FY25

This filer reports no gross profit or operating income line, so those margins are not drawn.

The receipt · income statement · FY21–FY25 USD millions except per-share & ratios · hover a line for its definition
USD millions except per-share & ratios
Line itemTTM †FY25FY24FY23FY22FY21YoYCAGR 21→25
Revenue & profitability
Revenue
—0.00.00.00.00.0——
Cost of revenue
—0.00.00.00.00.0——
Gross profit
—0.00.00.00.00.0——
Research & development
1,093.0794.3476.6332.3169.578.4▲66.6%+78.4%
Selling, general & admin
138.2129.492.960.739.825.3▲39.3%+50.4%
Total operating expenses
1,231.2923.7569.5468.0232.3103.7▲62.2%+72.8%
Operating incomefeeds ROC rank
−1,231.2−923.7−569.5−468.0−232.3−103.7▼62.2%—
Other income, net
84.4157.0105.665.88.83.6——
Pretax income
−1,146.8−766.6−463.9−402.3−223.5−100.1▼65.2%—
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−1,148.5−766.6−463.9−402.3−223.5−100.1▼65.2%—
Per share
Diluted EPSbuyback-sensitive
−8.07−5.63−3.80−4.14−3.44−1.93▼48.2%—
Diluted shares (mn)
148.91136.09122.0097.1664.8851.92▲11.6%+27.2%
Margins
† TTM = trailing four quarters through 2026-09-30.
FY18 – FY20 · 3 more years
Unlock the full history →
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-02-24 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.